EyePoint Pharmaceuticals was listed on Nasdaq, accompanied by rating updates from TD Cowen (downgrade) and Jefferies (upgrade).
1 report, 1 independent
Updated Sep 27
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
EyePoint Pharmaceuticals was listed on Nasdaq, accompanied by rating updates from TD Cowen (downgrade) and Jefferies (upgrade).
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
EyePoint Pharmaceuticals (United Kingdom)
company specialising in the application of microelectromechanical systems (MEMS) and nanotechnology to drug delivery
Nothing else this week.
-
Nasdaq
American fully electronic stock exchange
-
TD Cowen
American investment bank
Nothing else this week.
Related events
- TD Cowen boosted its price target and gave a buy rating for Jazz Pharmaceuticals.
- Multiple financial firms, including TD Cowen, Goldman Sachs, and Mizuho, issued various rating changes and price target updates across several stocks.
- TD Cowen and Scotiabank provided ratings and price targets for Devon Energy.
- Multiple financial institutions, including RBC, UBS, and Citi, issued rating and price target updates for Addus HomeCare Corporation on November 12, 2026.
- Multiple financial firms issued rating and price target updates on November 4, 2026.